A Rollover study for patients who received tremelimumab in other protocols, to allow the patients access to tremelimumab until this agent becomes commercially available or development is discontinued.

Study identifier:D4881C00024

ClinicalTrials.gov identifier:NCT00378482

EudraCT identifier:2008-000989-23

CTIS identifier:N/A

Study Complete

Official Title

A Rollover Protocol For Patients Who Received tremelimumab (CP-675,206 ) In Other Protocols

Medical condition

Colorectal Neoplasms

Phase

Phase 2

Healthy volunteers

No

Study drug

CP-675,206 (Tremelimumab)

Sex

All

Actual Enrollment

37

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 05 Mar 2007
Primary Completion Date: 27 Oct 2023
Study Completion Date: 27 Oct 2023

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Single Group Assignment
Masking: Open
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria